Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:47:58 EDT Fri 01 Aug 2025
Enter Symbol
or Name
USA
CA



Q:LXRX - LEXICON PHARMACEUTICALS INC - https://www.lexpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
LXRX - Q0.41.01·1.350.11.071,138.91,1542,4971.07  1.10  1.04012.175  0.283619:45:20Jul 3115 min RT 2¢

Recent Trades - Last 10 of 2497
Time ETExPriceChangeVolume
19:45:20Q1.090.0217
19:36:34Q1.090.023
18:48:02Q1.090.02100
18:45:21Q1.090.025
18:43:21Q1.06-0.0110
18:42:14Q1.08930.019315
17:56:22Q1.090.021
17:35:52Q1.110.04600
17:35:41Q1.090.0231
17:29:25Q1.090.02275

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-31 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-07-23 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
2025-07-18 08:00U:LXRXNews ReleaseLexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
2025-06-23 08:00U:LXRXNews ReleaseData Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
2025-06-18 08:30U:LXRXNews ReleaseLexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
2025-05-29 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
2025-05-19 08:00U:LXRXNews ReleaseSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology
2025-05-13 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates
2025-05-06 16:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference
2025-05-06 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
2025-04-02 08:00U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
2025-03-28 07:30U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
2025-03-07 08:30U:LXRXNews ReleaseLexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
2025-03-06 16:00U:LXRXNews ReleaseLexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-04 16:15U:LXRXNews ReleaseLexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
2025-03-03 07:00U:LXRXNews ReleaseLexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
2025-03-02 16:13U:LXRXNews ReleaseLexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
2025-02-18 08:00U:LXRXNews ReleasePublished Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
2025-01-21 08:00U:LXRXNews ReleaseLexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
2025-01-02 08:00U:LXRXNews ReleaseLexicon Appoints Scott Coiante as Chief Financial Officer